米拉贝隆与维贝格隆治疗女性膀胱过度活动症疗效与安全性的比较:随机对照试验的系统综述与Meta分析
本研究遵循PRISMA指南,对PubMed、EMBASE、Cochrane Library和Web of Science数据库中关于米拉贝隆与维贝格隆治疗女性膀胱过度活动症(OAB)的随机对照试验(RCT)进行Meta分析。共纳入3项RCT、371例患者。结果显示维贝格隆在缓解急迫性尿失禁方面优于米拉贝隆[均数差(MD)=0.25,95%置信区间(CI)0.04至0.47,p=0.02],其余疗效指标及安全性指标两组间无显著差异。结论认为两者疗效与安全性相似,维贝格隆可能更有效缓解急迫性尿失禁。
要点
- 维贝格隆在缓解女性OAB急迫性尿失禁方面优于米拉贝隆(MD=0.25,95%CI 0.04至0.47,p=0.02)。
- 两组在OABSS、急迫感、生活质量、每次排尿平均尿量方面无显著差异。
- 两组总不良事件、口干、便秘、残余尿升高、头晕等安全性结局无显著差异。
核心结论
- 在女性OAB患者中,米拉贝隆与维贝格隆的疗效和安全性相似。
- 维贝格隆在缓解急迫性尿失禁方面可能比米拉贝隆更有效。
研究设计与样本
- 本研究为遵循PRISMA指南的系统综述与Meta分析。
- 检索PubMed、EMBASE、Cochrane Library和Web of Science数据库中关于米拉贝隆与维贝格隆治疗女性OAB的随机对照试验(RCT)。
- 共纳入3项RCT,涉及371例患者。
主要发现
- 维贝格隆在缓解女性OAB急迫性尿失禁方面优于米拉贝隆(MD=0.25,95%CI 0.04至0.47,p=0.02)。
- 维贝格隆与米拉贝隆在OAB症状评分(OABSS)方面相似(MD=0.22,95%CI -0.32至0.76,p=0.42)。
- 维贝格隆与米拉贝隆在急迫感方面相似(MD=0.15,95%CI -0.08至0.38,p=0.20)。
- 维贝格隆与米拉贝隆在生活质量(QOL)方面相似(MD=-0.18,95%CI -0.49至0.13,p=0.26)。
- 维贝格隆与米拉贝隆在每次排尿平均尿量方面相似(MD=-6.16,95%CI -21.50至-9.17,p=0.43)。
关键数值与推荐
- 安全性结局:总不良事件(TAEs)[比值比(OR)=0.75;95%CI:0.44至1.26;p=0.28]。
- 安全性结局:口干(OR=1.01;95%CI:0.36至2.81;p=0.99)。
- 安全性结局:便秘(OR=0.69;95%CI:0.33至1.44;p=0.32)。
- 安全性结局:残余尿(PVR)升高(OR=0.35;95%CI:0.05至2.23;p=0.26)。
- 安全性结局:头晕(OR=1.02;95%CI:0.14至7.31;p=0.98)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the efficacy and safety of mirabegron and vibegron in female patients with overactive bladder (OAB). METHODS: This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A meta-analysis of randomized controlled trials (RCTs) referred to the use of mirabegron and vibegron in female patients with OAB from PubMed, EMBASE, Cochrane Library, and Web of Science databases was performed. RESULTS: Three RCTs involving 371 patients were included. We found that vibegron was more effective in relieving urgency urinary incontinence in females with OAB compared to mirabegron [mean difference (MD)=0.25, 95% confidence interval (CI) 0.04 to 0.47, p=0.02]. And vibegron was similar to mirabegron in OAB symptom score (OABSS) [MD=0.22, 95% CI -0.32 to 0.76, p=0.42], urgency (MD=0.15, 95% CI -0.08 to 0.38, p=0.20), quality of life (QOL) (MD=-0.18, 95% CI -0.49 to 0.13, p=0.26), mean volume voided per micturition (MD=-6.16, 95% CI -21.50 to -9.17, p=0.43). In terms of the safety outcomes, there were no significant differences between mirabegron and control groups in terms of the total adverse events (TAEs) [odds ratio (OR)=0.75; 95% CI: 0.44 to 1.26; p=0.28], dry mouth (OR=1.01; 95% CI: 0.36 to 2.81; p=0.99), constipation (OR=0.69; 95% CI: 0.33 to 1.44; p=0.32), elevated post-void residual (PVR) (OR=0.35; 95% CI: 0.05 to 2.23; p=0.26), and dizziness (OR=1.02; 95% CI: 0.14 to 7.31; p=0.98). CONCLUSION: In female OAB patients, the efficacy and safety of mirabegron and vibegron were similar. Vibegron may be more effective than mirabegron in relieving urgency urinary incontinence.
引用
- Liang P, Yu L, Xia B, et al. Comparative Efficacy and Safety of Mirabegron and Vibegron in Female Patients With Overactive Bladder: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Urology. 2025. PMID: 39970965. doi:10.1016/j.urology.2025.02.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。